Intas Pharma to donate 2 million hydroxychloroquine tablets for WHO-endorsed study

?OUR BUREAU Mumbai | Updated on March 30, 2020 Published on March 30, 2020

Intas Pharmaceuticals Ltd is collaborating on a World Health Organization-endorsed study into the prevention of Covid-19 using hydroxychloroquine, a drug that may have an effect in preventing and/or reducing symptoms of the coronavirus, said a note from the company.

The global COPCOV (chloroquine/hydroxychloroquine prevention of Covid-19 in the healthcare setting; a randomised, placebo-controlled prophylaxis) study involves 40,000 frontline healthcare workers who are caring for Covid-19 patients and is due to start shortly, said Intas, touted to be the largest supplier by volume of generic medicines to the UK NHS.

COPCOV will be led by scientists from the University of Oxford and funded by the Wellcome Trust. The study pools the resources of international experts across multiple continents. Intas will provide up to two million tablets of hydroxychloroquine to the trial, free of charge, along with two million tablets of matched placebo (medicines that look real, but don’t contain the active ingredient).

‘Race against time’

Explaining what prompted the study, William Schilling, co-lead investigator, Research Physician and Infectious Diseases/ Microbiology Registrar, Mahidol Oxford Tropical Medicine Research Unit in Thailand, said: “We are in a race against time to find effective treatments and preventive measures as the Covid-19 pandemic grows. What we already know is that chloroquine has antiviral activity against SARS-CoV-2 in cell culture, as it does for the related SARS-CoV.”

The Intas statement cited professor Sir Nicholas White, Wellcome Trust Fellow and consultant in infectious diseases at the University of Oxford, as saying, “The hypothesis for this study is that chloroquine and hydroxychloroquine might both slow viral replication in exposed subjects, attenuating or preventing the infection. Given the extensive experience in clinical practice, established safety and tolerability profile, if it proves effective then it would be a readily deployable and affordable preventive measure for high risk individuals such as healthcare workers”.

Binish Chudgar, Vice-Chairman and Managing Director, Intas Pharmaceuticals, said that their teams were working round-the-clock, in challenging times, to manufacture the required hydroxychloroquine and matching-placebo for this vital study.

Published on March 30, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.